Palopegteriparatide in APS-1: Serial Cases Supporting Reduced-Dose Initiation
Palopegteriparatide (Yorvipath), a long-acting parathyroid hormone (PTH) 1–34 prodrug approved for adults with chronic hypoparathyroidism, has a recommended starting dose of 18 mcg once daily. This regimen was established predominantly in patients with postsurgical hypoparathyroidism. Evidence in autoimmune polyendocrine syndrome type 1 (APS-1)-associated hypoparathyroidism is limited to two participants in the pivotal phase 3 trial. We describe our single-centre experience with initiating palopegteriparatide in four adults with APS-1-associated hypoparathyroidism. The first two patients started palopegteriparatide at the label-recommended dose of 18 mcg once daily and developed severe hypercalcaemia within 7 days, with peak albumin-adjusted calcium of 3.60 and 3.19 mmol/L, respectively. Both were asymptomatic, and hypercalcaemia was detected by biochemical monitoring. Treatment was discontinued, and aggressive inpatient hydration and gradual re-titration were required before serum calcium stabilized. Given this experience, the subsequent two patients were initiated at a reduced dose of 9 mcg once daily. Neither developed hypercalcaemia, and both reached and maintained albumin-adjusted calcium within the reference range while discontinuing conventional supplementation. Higher pre-treatment conventional-therapy requirements, differing baseline calcium and renal function, and consecutive treatment limit attribution of these responses to the starting dose alone. These hypothesis-generating observations suggest that patients with APS-1 may benefit from a lower starting dose, together with structured early calcium monitoring, timely adjustment of conventional therapy and clear communication with patients throughout titration and maintenance.
Authors
- Andrej Janež (ORCID: https://orcid.org/0000-0002-6594-5254)
- Tomaž Kocjan (ORCID: https://orcid.org/0000-0001-8606-6825)
- Rok Herman (ORCID: https://orcid.org/0000-0002-6053-5686)
- Mojca Jensterle (ORCID: https://orcid.org/0000-0002-8861-8803)
- Andrijana Koceva (ORCID: https://orcid.org/0009-0004-7407-9732)
Institutions
- University of Ljubljana (SI)
- Ljubljana University Medical Centre (SI)
- University of Maribor (SI)
- University Clinical Centre Maribor (SI)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1093/ejendo/lvag225
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00